Bausch Health Companies Inc. (BHC)
NYSE: BHCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BHC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.08B
- Forward P/E
- 1.89
- EPS (TTM)
- -$2.26
- Dividend yield
- None
- Ex-dividend date
- Nov 10, 2010
- 52-week range
- 4.33 – 9.04
- Day range
- 8.12 – 8.55
- Volume / Avg
- 3.84M / 3.16M
- Beta
- —
- Shares outstanding
- 374.27M
52-week range
BHC stock today
Shares of Bausch Health Companies (BHC) finished lower on Nov 20 at $8.22, a drop of 3.97% or $0.34 per share, versus the S&P 500's 3.70% decline. Shares are 9.1% below their 52-week high of $9.04, set on Oct 29, 2026 and 89.8% above the 52-week low of $4.33, near the top of the past year's range. BHC is up 18.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 36.3%.
Bausch Health Companies has posted a net loss over the last twelve months (EPS of -$2.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Bausch Health Companies
Company profileBausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Thomas J. Appio
- Headquarters
- Laval, QC
- Employees
- 20,300
- Website
- bauschhealth.com
Financial highlights
Full financialsIn fiscal 2025, Bausch Health Companies generated $10.27 billion in revenue, up 6.7% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $157.0 million, for a net margin of 1.5% versus a median of -6.8% in the prior 5 years. Operating margin was 17.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $10.27B | $9.63B | $8.76B | $8.12B | $8.43B |
| Growth | +6.66% | +9.91% | +7.79% | -3.68% | +5.07% |
| Net income | $157.00M | $-46.00M | $-592.00M | $-225.00M | $-948.00M |
| EPS (diluted) | $0.42 | $-0.13 | $-1.62 | $-0.62 | $-2.64 |
Analyst forecast
ForecastConsensus (7 analysts)
hold
Avg. price target
$8.40+2.19%
- Strong buy 0
- Buy 0
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $1.16 vs $1.08
- Surprise
- +7.41%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $1.00
- Ex-dividend date
- Nov 10, 2010
BHC news
All BHC news- Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026PR Newswire
- Bausch Health Companies Consensus Price Target Increased by 11.58% to $7.29Nasdaq
- Healthcare Stocks Rise: GKOS Surges 33%, TDOC Gains 30%, BHC Advances 26%, MESO Jumps Over 16%NasdaqBHC, GKOS, MESO, TDOC
- BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesNasdaqBHC, TGTX, IOVA, AMRX
- Bausch Health (BHC) Q3 2026 Earnings Call TranscriptNasdaq
- Bausch Health Companies Inc. Reports Third Quarter 2026 Consolidated Revenues of $2.94 billionNasdaq
- Bausch Health Companies Inc. Q3 Profit ClimbsNasdaq
- Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027PR Newswire
Bausch Health Companies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs BHC |
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs BHC |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs BHC |
| LEGNLegend Biotech Corporation ADR | 15.25 | -5.28% | $2.96B | vs BHC |
| ACADACADIA Pharmaceuticals Inc. | 17.11 | -2.73% | $2.96B | vs BHC |
| DYNDyne Therapeutics Inc. | 15.50 | -3.31% | $2.90B | vs BHC |
| TLXTelix Pharmaceuticals Limited ADR | 8.37 | -3.90% | $2.84B | vs BHC |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs BHC |
Indexes, lists and sector
Bausch Health Companies stock FAQ
What is Bausch Health Companies's stock price today?
BHC last traded at $8.22 as of Nov 20, 4:00 PM EST, down 3.97% on the day. Prices are delayed at least 15 minutes.
Does Bausch Health Companies pay a dividend?
Yes. Bausch Health Companies pays $0.00 per share annually. The most recent dividend of $1.00 had an ex-dividend date of Nov 10, 2010.
Who is Bausch Health Companies's CEO?
Mr. Thomas J. Appio is the chief executive officer of Bausch Health Companies Inc., which has about 20,300 employees.
Has BHC ever split its stock?
Yes. The most recent BHC stock split was a 2-for-1 split on Oct 16, 2000, one of 3 splits on record.
What is the BHC 52-week high?
The 52-week high for BHC is $9.04 and the 52-week low is $4.33. The stock is currently 9.1% below its high.